family with sequence similarity 227 member AGenealiases: []
Q-omics provides the consensus-scored FAM227A profile across patient tissues and cancer cell-line models. FAM227A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FAM227A is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, FAM227A RNA expression shows 19,905 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, COAD, and UVM as cancer lineages where FAM227A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM227A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM227A survival associations across molecular data types. FAM227A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM227A RNA expression–survival associations across cancer types. High FAM227A expression shows unfavorable associations in KIRC, LIHC, THCA and PRAD, but favorable associations in READ and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FAM227A RNA expression.
This table summarizes FAM227A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for FAM227A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM227A shows lower tumor expression in KICH and THCA and higher tumor expression in COAD, BLCA, CHOL and READ. The COAD box plot shows higher FAM227A RNA expression in tumor versus normal tissue (log2 FC = +0.500, t-test p < 0.001).
This table shows molecular features associated with FAM227A in patient tissues and cancer cell lines. In patient samples, FAM227A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM227A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Lymphoma.
